<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02604628</url>
  </required_header>
  <id_info>
    <org_study_id>1</org_study_id>
    <nct_id>NCT02604628</nct_id>
  </id_info>
  <brief_title>Increasing Community-acquired Pneumonia Protocol Adherence by Antibiotic Stewardship</brief_title>
  <acronym>CAP-PACT</acronym>
  <official_title>Community-acquired Pneumonia: Increasing Protocol Adherence by Antibiotic Stewardship in a Stepped Wedge Cluster- Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>UMC Utrecht</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effect of a multifaceted antibiotic stewardship
      intervention on protocol adherence of moderate-severe community-acquired pneumonia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to show a decrease in broad-spectrum antibiotics with a
      non-inferiority in 90-day mortality. Hospitals with a pre-intervention protocol adherence of
      &gt;70% are excluded from the primary analysis. Primary analysis will be done with a mixed
      effects model with a random effects for clusters and time. Crude outcomes and outcomes
      adjusted for potential confounders will be reported. Primary analysis will be tested
      one-sided for a decrease in mortality. Secondary analysis to test two-sided for mortality
      will be performed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2015</start_date>
  <completion_date type="Anticipated">August 2018</completion_date>
  <primary_completion_date type="Actual">November 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Broad-spectrum antibiotic use</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <description>Antibiotic use will be registered during hospital stay</description>
  </primary_outcome>
  <primary_outcome>
    <measure>90-day mortality</measure>
    <time_frame>90-days after hospital admission</time_frame>
    <description>All-cause mortality on day 90 from admission will be assessed from the municipal personal records database</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>30-day mortality</measure>
    <time_frame>30-days after hospital admission</time_frame>
    <description>All-cause mortality on day 30 from admission will be assessed from the municipal personal records database</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clostridium difficile infections</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <description>Clostridium difficile polymerase chain reaction (PCR) outcomes will be registered during hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of intravenous antibiotic treatment</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complications</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <description>Complications of pneumonia during admission are registered from the clinical record</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital readmissions</measure>
    <time_frame>Hospital readmissions within 30 days of hospital admission will be registered</time_frame>
    <description>Hospital readmissions will be registered 30 days after hospital admission</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antibiotic switches</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <description>Switches from intravenous to oral (and vice versa) and switches from broad-spectrum to narrow-spectrum (and vice versa) will be registered</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intensive Care admissions</measure>
    <time_frame>Participants will be followed for the duration of hospital stay, an expected average of 1 week</time_frame>
    <description>Intensive Care admissions will be registered during hospital stay</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">5400</enrollment>
  <condition>Community-acquired Pneumonia</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will be treated as standard of care.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Antibiotic Stewardship Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated as standard of care. The Antibiotic Stewardship Intervention will be targeted at the physicians treating the community-acquired pneumonia patients. The purpose of the intervention is to increase prescription concordance with the national guideline for community-acquired pneumonia.</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Antibiotic Stewardship Intervention</intervention_name>
    <description>The Antibiotic Stewardship Intervention will consist of education, motivating opinion leaders, adapting a pragmatic disease severity classification and prospective audit and feedback.</description>
    <arm_group_label>Antibiotic Stewardship Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients diagnosed with CAP who get admitted to a non-ICU department are eligible for
             inclusion.

        Exclusion Criteria:

          -  Patients aged below 18 years

          -  Residence in a nursing home or long-term care facility in the last 14 days

          -  Patients hospitalized in an acute care hospital for two or more days in the last 14
             days

          -  Patients with a history of Cystic Fibrosis

          -  Patients with immunodeficiency, defined as having one or more of the following
             criteria:

               -  HIV infection with a last CD4 count of &lt;300//Î¼L

               -  Cytotoxic chemotherapy or radiotherapy in the previous 3 months

               -  Chronic hemodialysis &gt; 3 months

               -  History of receiving an organ or bone marrow transplant

               -  Using immunosuppressive therapy, include corticosteroid treatment only when
                  dosage is high (&gt;0,5mg/kg/day) for a longer period of time (&gt;14 days)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marc J.M. Bonten, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UMC Utrecht</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Valentijn A. Schweitzer, MD, Msc</last_name>
    <phone>+31( 0)88 75 696 14</phone>
    <email>V.A.Schweitzer-2@umcutrecht.nl</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Inger van Heijl, PharmD, Msc</last_name>
    <phone>+31 (0)88 753 37 37</phone>
    <email>ivanheijl@tergooi.nl</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Noordwest Ziekenhuisgroep</name>
      <address>
        <city>Alkmaar</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>W.G. Boersma, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilhelmina hospital</name>
      <address>
        <city>Assen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Amphia hospital</name>
      <address>
        <city>Breda</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>prof. J.A.J.W. Kluytmans, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>C.M. Verduin, MD, PhD</last_name>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Catharina hospital</name>
      <address>
        <city>Eindhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>H.S.M. Ammerlaan, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medisch Spectrum Twente</name>
      <address>
        <city>Enschede</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Ziekehuisgroep Twente</name>
      <address>
        <city>Hengelo</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>J.M.M. Roorda-van der Vegt, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tergooi</name>
      <address>
        <city>Hilversum</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>P. van der Linden, PharmD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>J.W. Dorigo-Zetsma, MD, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>I. van Heijl, PharmD, Msc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Erasmus MC</name>
      <address>
        <city>Rotterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Terminated</status>
  </location>
  <location>
    <facility>
      <name>Diakonessenhuis</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>S.U.C. Sankatsing, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>UMC Utrecht</name>
      <address>
        <city>Utrecht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>prof. M.J.M. Bonten, MD, PhD</last_name>
    </contact>
    <contact_backup>
      <last_name>C.H.E. Boel, MD, PhD</last_name>
    </contact_backup>
    <investigator>
      <last_name>V. A. Schweitzer, MD, Msc</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maxima Medisch Centrum</name>
      <address>
        <city>Veldhoven</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>D.R.A.J. de Munck, MD, PhD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Langeland hospital</name>
      <address>
        <city>Zoetermeer</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>A.K. van der Bij, MD, PhD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 10, 2015</study_first_submitted>
  <study_first_submitted_qc>November 11, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 13, 2015</study_first_posted>
  <last_update_submitted>May 1, 2018</last_update_submitted>
  <last_update_submitted_qc>May 1, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 4, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>MJM Bonten</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <keyword>Pneumonia</keyword>
  <keyword>Antibiotic Stewardship</keyword>
  <keyword>Stepped wedge</keyword>
  <keyword>Antibiotic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

